Ann: Quarterly Update and Appendix 4C, page-6

Kaboom! High silicon content anode achieves 500 cycles at 80% capacity retention. hang unto your wheel chairs ADO investors we're off to the battery races !

• Key deliverables continue to progress to previously advised schedule.
• Completion of EuGeni SARS-CoV-2 Ag RDT1 Australian clinical trial in July, with an overall sensitivity of 87.75% and high sensitivity of 97.5% at ≤CT 30 within 0 – 3 days post symptom onset.
• AnteoTech has fielded an increasing number of inbound enquiries for assay development services incorporating AnteoBind.
• Continued strengthening of market position of AnteoX, results from internal testing validate claims for high silicon content anodes, aiding in improved battery life cycles.
• High silicon content anode achieves 500 cycles at 80% capacity retention.